MBX Biosciences, Inc. MBX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about MBX Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MBX Biosciences, Inc.'s cash & equivalents?
- MBX Biosciences, Inc. (MBX) reported cash & equivalents of $45.21M in Q1 2026.
- How has MBX Biosciences, Inc.'s cash & equivalents changed year-over-year?
- MBX Biosciences, Inc.'s cash & equivalents increased by 51.2% year-over-year, from $29.9M to $45.21M.
- What is the long-term trend for MBX Biosciences, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s cash & equivalents has grown at a 57.1% compound annual growth rate (CAGR), from $30.52M to $75.29M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.